nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Addiction/Reward"

 

Non-Invasive Brain Stimulation For Smoking Cessation
May 4, 2022   

A recent review and meta-analysis of randomized controlled trials of non-invasive brain stimulation for the treatment of tobacco use disorder found that non-invasive brain stimulation may improve smoking abstinence rates for up to 6 months after smoking cessation compared to control. Current smoking cessation rates with no medical intervention are approximately...
 Continue reading (Members only)
Vortioxetine in Patients with Major Depressive and Alcohol Use Disorders
April 17, 2022   

Major depressive disorder (MDD) is often found comorbid with alcohol use disorder (AUD) and patients with MDD+AUD often have a worsened illness and prognosis. Response of MDD+AUD to classic antidepressants, including selective serotonin reuptake inhibitors (SSRIs), norepinephrine serotonin reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) is often unsatisfactory. In this study...
 Continue reading (Members only)
MDMA-Assisted Therapy Significantly Reduces Eating Disorder
April 10, 2022   

IThe comorbidity of Post-Traumatic Stress Disorder (PTSD) and Eating Disorders (EDs) has been well studied. This relationship is hypothesized to exist due to an overlap in distinct risk factors including female gender, familial history of psychiatric disorders, lack of social support, and a history of trauma...
 Continue reading (Members only)
Alcohol Consumption May Also Carry Risks To The Brain
April 1, 2022   

Heavy alcohol consumption has been known to be associated with neuronal loss, brain atrophy and poorer white matter fiber integrity. April is Alcohol Awareness Month and is meant to spread awareness and education about alcohol dependence and alcohol use disorder...
 Continue reading
Intranasal Oxytocin for Cocaine Dependence?
February 25, 2022   

Findings from drug addiction studies suggest that oxytocin treatment (OT) has potential therapeutic benefits. A recent 6-week randomized, double-blind, outpatient clinical trial study was conducted by investigating the effect of daily intranasal oxytocin...
 Continue reading (Members only)
The Impact of Alcohol and Other Substance Use Disorders on Mortality in Patients With Eating Disorders
January 27, 2022   

Eating disorders are highly associated with mortality, and anorexia nervosa is the second most lethal psychiatric disorder, surpassed only by substance use disorder (SUD). Patients with eating disorders frequently have comorbid SUDs. In a recent retrospective cohort study using...
 Continue reading
FDA Warns Orally Dissolving Buprenorphine Tied to Dental Problems
January 12, 2022   

The U.S. Food and Drug Administration is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues...
 Continue reading (Members only)
2021 NEI Congress Recreational Drug Use Workshop
November 4, 2021   

The 2021 NEI Congress kicked off with a pre-conference workshop on recreational drugs—both as illicit agents and as potential therapeutic options. Roger S. McIntyre, MD, FRCPC began the workshop with “An Update on Psychedelics,” explaining both the historical use of these agents as therapeutic entities as well as the scientific rationale for the renewed interest in psychedelic-assisted therapy as a treatment paradigm. At present...
 Continue reading
Methamphetamine Use, Overdose Deaths From Psychostimulants Are Increasing
October 14, 2021   

It is estimated that from 2015 to 2019, the number of overdose deaths from psychostimulants other than cocaine (namely methamphetamines) has more than doubled. In this cross-sectional study involving nearly 200,000 individuals aged 18-64, the authors sought to uncover some of the factors associated with this increase in overdose deaths from methamphetamines...
 Continue reading (Members only)
Effects of Gabapentin With Abstinence in Alcohol Use Disorder
August 18, 2021   

Gabapentin blocks calcium channels containing the alpha 2 delta 1 subunit and has other actions that may affect both glutamatergic and GABAergic neurotransmission, much the same as drinking alcohol does. It is FDA-approved for the treatment of neuralgia, partial seizures, and restless legs syndrome; however, recent studies are investigating gabapentin as a potential medication for mitigating withdrawal and preventing relapse in alcohol use disorder...
 Continue reading
123456789
Top of Page